GINA reiterates montelukast safety warning
The 2024 GINA guideline update reminds prescribers of the potential risk of neuropsychiatric adverse events in patients receiving montelukast, including:[1]
new-onset nightmares,
behavioral and mood problems (e.g., agitation, hyperactivity, irritability, nervousness, aggression), and
suicidal ideation.
Healthcare professionals should consider the benefits and risks before prescribing montelukast, and have an open discussion with parents about potential adverse effects. Healthcare professionals and patients should be alert to, and monitor for, serious behavior and mood-related changes during treatment.
Summary
Definition
History and exam
Key diagnostic factors
- wheezing episode triggers
- increased work of breathing
- features of atopic disease
- history of response to treatment within appropriate time frame
- family history of asthma
- history of passive or active tobacco smoking
Other diagnostic factors
- age >3 years
- dry nighttime cough
- dyspnea on exertion
- expiratory wheezing
- chest wall deformity
Risk factors
- allergic sensitization
- atopic disease
- respiratory tract infections in early life
- serum eosinophilia
- family history of asthma or atopy
- gene polymorphisms and epigenetics
- passive or active cigarette smoking
- vaping
- maternal smoking in pregnancy
- abnormal lung function and airway hyperresponsiveness
- indoor and outdoor air pollution
- low socioeconomic status
- pesticide exposure
- male sex
- obesity
- gastroesophageal reflux disease (GERD)
- obstructive sleep apnea (OSA)
- assisted reproductive technologies
- cesarean section
- intestinal microbiota
- acid-suppressive drug use in pregnancy and childhood
- acetaminophen use in pregnancy
- antibiotic use in pregnancy
Diagnostic tests
1st tests to order
- spirometry
- peak expiratory flow (PEF)
- response to bronchodilator
Tests to consider
- airway challenge tests
- exercise challenge test
- CBC
- sweat test
- sputum culture
- skin prick testing
- chest x-ray
- electron micrograph ciliary studies
- chest CT
- sinus CT
- bronchoscopy
- bronchoalveolar lavage
Emerging tests
- fractional expired nitric oxide (FeNO)
Treatment algorithm
age 0 to 5 years
age 6 to 11 years
Contributors
Authors
Paul D. Robinson, MBChB, MRCPCH, FRACP, PhD, ATSF
Respiratory and Sleep Physician
Queensland Children's Hospital
Conjoint Professor
Child Health Research Centre
University of Queensland
Brisbane
Queensland
Australia
Disclosures
PDR declares that he has no competing interests.
Anne Chang, MBBS, FRACP, MPHTM, PhD, FAPSR, FThorSoc, FAHMS
Professor
Respiratory and Sleep Physician
Queensland Children's Hospital
Queensland University of Technology
Brisbane
Menzies School of Health Research
Charles Darwin University
Darwin
Australia
Disclosures
AC is an author for UptoDate and receives chapter royalties. She is an author of a number of references cited in this topic.
Peer reviewers
Kenan Haver, MD
Associate Professor of Pediatrics, Harvard Medical School
Boston Children's Hospital
Division of Pulmonary Medicine
Boston
MA
Disclosures
KH receives royalties from UpToDate.
Peter Griffiths, MBChB
General Practitioner
Harborne Medical Practice
Birmingham
UK
Disclosures
PG declares that he has no competing interests.
Differentials
- Bronchiolitis
- Episodic (viral) wheeze
- Inhaled foreign body
More DifferentialsGuidelines
- Global strategy for asthma management and prevention
- GEMA 5.3. Spanish guideline on the management of asthma
More GuidelinesPatient information
Asthma in children: what is it?
Asthma in children: what treatments work?
More Patient informationVideos
Expiratory wheeze
Polyphonic wheeze
More videos- Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer